Contact
searchSearch
HMP Global
Login

News

Catherine Coombs, MD
Conference Coverage
Evolving Treatment Strategies for Patients With Chronic Lymphocytic Leukemia
06/28/2025
Catherine Coombs, MD
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in...
06/28/2025
Oncology
Constantine Tam, MD
Conference Coverage
Zanubrutinib for Patients With del(17p) CLL and SLL: 5-Year Follow-Up From the SEQUOIA Trial
06/03/2025
Constantine S. Tam
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses...
06/03/2025
Oncology
Constantine Tam, MD
Conference Coverage
Zanubrutinib for Patients With del(17p) CLL and SLL: 5-Year Follow-Up From the SEQUOIA Trial
06/03/2025
Constantine S. Tam
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses...
06/03/2025
Oncology
News
Allogeneic Stem Cell Transplantation Beneficial for Patients With High-Risk or R/R Chronic Lymphocytic Leukemia
05/31/2025
Emily Estrada
Allogeneic stem cell transplantation demonstrated improved survival and cancer outcomes among patients with chronic lymphocytic leukemia, according to a retrospective study.
Allogeneic stem cell transplantation demonstrated improved survival and cancer outcomes among patients with chronic lymphocytic leukemia, according to a retrospective study.
Allogeneic stem cell...
05/31/2025
Oncology
News
Zanubrutinib Demonstrates Efficacy and Tolerability Among BTK Inhibitor Intolerant Patients With CLL/SLL
05/28/2025
Emily Estrada
For patients previously intolerant to ibrutinib and/or acalabrutinib, zanubrutinib demonstrated improved safety and tolerability for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
For patients previously intolerant to ibrutinib and/or acalabrutinib, zanubrutinib demonstrated improved safety and tolerability for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
For patients previously...
05/28/2025
Oncology
News
Real-World Study Confirms Efficacy and Safety of Venetoclax-Based Regimens for Chronic Lymphocytic Leukemia
05/22/2025
Emily Estrada
Venetoclax-based regimens demonstrated efficacy and safety among patients with chronic lymphocytic leukemia in a real-world setting.
Venetoclax-based regimens demonstrated efficacy and safety among patients with chronic lymphocytic leukemia in a real-world setting.
Venetoclax-based regimens...
05/22/2025
Oncology
John Allan, MD
Videos
Novel Targeted Therapies for Patients With Chronic Lymphocytic Leukemia
02/24/2025
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new...
02/24/2025
Oncology
Craig Sauter, MD
Conference Coverage
Exploring CAR T-Cell Therapy for Aggressive Lymphomas Including DLBCL and CLL/SLL With Richter’s Transformation
10/18/2024
Craig Sauter, MD
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Oncology
Kerry Rogers, MD
Conference Coverage
Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?
09/23/2024
Kerry Rogers, MD
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry...
09/23/2024
Oncology
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
Moritz Furstenau, MD
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use